Healthcare Services

Ischemia Reperfusion Injury Market Growth Outlook Indicating Expansion To $2.38 Billion By 2030

June 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Ischemia Reperfusion Injury Market During The Forecast Period?

The ischemia reperfusion injury market has demonstrated substantial growth in recent years. It is forecast to grow from $1.67 billion in 2025 to $1.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.5%. The expansion witnessed in previous periods stemmed from factors such as the increasing incidence of cardiovascular diseases, a rise in organ transplant procedures, the growing prevalence of stroke and heart attack cases, advancements in acute care infrastructure, and the heightened use of pharmacological therapies.

The ischemia reperfusion injury market size is expected to undergo significant expansion in the upcoming years, projected to reach $2.38 billion by 2030, displaying a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period is driven by factors such as the increasing research in stem cell and gene therapy, a growing acceptance of non-pharmacological conditioning therapies, increased investment in critical care technologies, the expansion of clinical trials for agents protecting mitochondria, and a better understanding of ischemia-reperfusion mechanisms. Major trends anticipated in this period include AI-powered prediction of ischemia-reperfusion injury outcomes, the development of precision therapeutics for cellular and mitochondrial protection, data-centric clinical decision support systems, connected monitoring of tissue perfusion and oxygenation, and advanced manufacturing techniques for targeted therapeutics.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22025&type=smp

What Important Drivers Are Powering The Ischemia Reperfusion Injury Market Growth?

An increasing occurrence of cardiovascular diseases is projected to stimulate the expansion of the ischemia-reperfusion injury market in the coming years. These ailments, encompassing conditions like coronary artery disease, heart failure, and stroke, are a category of disorders impacting the heart and its vascular system. The surge in cardiovascular disease cases stems from an aging populace and detrimental lifestyle decisions, where diets rich in saturated fats, sugar, and salt, coupled with insufficient physical activity, contribute to heightened rates of obesity, hypertension, and diabetes – all key contributors to cardiovascular health issues. Ischemia-reperfusion injury exacerbates the progression of cardiovascular diseases by intensifying tissue damage via oxidative stress, inflammation, and cellular death, ultimately hindering heart function and elevating the likelihood of heart failure and other related complications. For example, reports from the US Centers for Disease Control and Prevention in October 2024 indicated that 919,032 individuals succumbed to cardiovascular disease in 2023, representing one in three deaths. Consequently, the rising incidence of cardiovascular diseases is fueling the expansion of the ischemia-reperfusion injury market. The growing frequency of organ transplantation is anticipated to boost the ischemia-reperfusion injury market moving forward. Organ transplantation involves the surgical transfer of a healthy organ from a donor to a recipient to replace an organ that is failing or damaged. The heightened rate of organ transplants is attributed to continuous advancements in medical technology and an increasing number of patients experiencing organ failure. Improvements in surgical techniques, immunosuppressive therapies, and methods for organ preservation have significantly enhanced the success rates of these procedures. Ischemia-reperfusion injury can be mitigated during organ transplantation through the use of sophisticated preservation techniques, which lessen the damage incurred during the ischemic period, thereby improving the transplanted organ’s survival and function upon reperfusion. For instance, in January 2024, data from the Organ Procurement and Transplantation Network, a US Department of Health and Human Services program, revealed that organ transplants from both living and deceased donors collectively reached 46,632 in 2023, marking an 8.7 percent increase compared to 2022. Of these, 39,679 procedures originated from deceased donors, indicating an 8.9 percent rise over the preceding year. Thus, the growing incidence of organ transplantation is propelling the growth of the ischemia-reperfusion injury market.

What Are The Major Segment Categories Within The Ischemia Reperfusion Injury Market?

The ischemia reperfusion injury market covered in this report is segmented –

1) By Treatment Type: Pharmacological Therapy, Non-pharmacological Therapy

2) By Application: Cardiovascular Diseases, Stroke, Organ Transplantation, Heart Attack

3) By End User: Hospitals, Clinics, Ambulatory Services

Subsegments:

1) By Pharmacological Therapy: Antioxidants, Anti-inflammatory Agents, Calcium Channel Blockers, Free Radical Scavengers, Nitric Oxide Donors, Mitochondrial Protective Agents

2) By Non-Pharmacological Therapy: Ischemic Preconditioning (IPC), Ischemic Postconditioning (IPO), Remote Ischemic Conditioning (RIC), Hypothermia Therapy, Mechanical Interventions

What Trends Are Driving Changes In The Ischemia Reperfusion Injury Market?

Key players in the ischemia-reperfusion injury market are concentrating on developing novel treatments, including dual-acting stroke therapeutics, aimed at boosting patient recuperation, decreasing impairment, and achieving better treatment results. These dual-acting neuroprotective drugs are sophisticated small-molecule compounds that blend selective modulation of NMDA receptors with antioxidant free-radical scavenging. This combination facilitates various benefits like lessening neuronal damage caused by reperfusion, enhancing tissue survival after occlusion, and aiding functional restoration. An example of this is GNT Pharma, a biopharmaceutical company from South Korea, which secured regulatory approval in July 2025 to commence multinational Phase 3 clinical trials for Nelonemdaz. This drug is a cutting-edge dual-acting neuroprotective agent specifically formulated to mitigate neuronal injury in individuals undergoing endovascular thrombectomy for acute ischemic stroke. This particular therapy works by selectively inhibiting NMDA receptor-mediated excitotoxicity and effectively scavenging free radicals to reduce oxidative harm. Ultimately, Nelonemdaz contributes to improved neuroprotection, better functional recovery, and enhanced outcomes following reperfusion in patients experiencing ischemic stroke.

Which Firms Are Competing In The Ischemia Reperfusion Injury Market?

Major companies operating in the ischemia reperfusion injury market are Pfizer Inc, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Sanofi, Merck KGaA, Takeda Pharmaceutical Company, Bayer AG, Amgen Inc, Otsuka Pharmaceutical Co Ltd, Simcere Innovation Inc, Faron Pharmaceuticals Oy, Faraday Pharmaceuticals Inc, Prolong Pharmaceuticals LLC, Angion Biomedica Corp, CalciMedica Inc, Athersys Inc, Oxitope Pharma BV, LUCA Science Inc

Access The Complete Ischemia Reperfusion Injury Market Report:

https://www.thebusinessresearchcompany.com/report/ischemia-reperfusion-injury-global-market-report

Which Region Has The Strongest Presence In The Ischemia Reperfusion Injury Market?

North America was the largest region in the ischemia reperfusion injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemia reperfusion injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Ischemia Reperfusion Injury Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22025&type=smp

Browse Through More Reports Similar to the Global Ischemia Reperfusion Injury Market 2026, By The Business Research Company

Myocardial Ischemia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/myocardial-ischemia-global-market-report

Acute Ischemic Stroke Diagnosis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-diagnosis-global-market-report

Acute Ischemic Stroke Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795